Retroviral protease inhibiting compounds

Details Retroviral protease inhibiting compounds Retroviral protease inhibiting compounds

2011-06-28

2011-06-28

O'Sullivan, Peter G (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C540S492000, C540S460000, C544S088000, C544S097000, C544S316000, C544S332000, C546S233000, C548S229000, C548S233000, C548S324100, C548S331500, C548S550000, C514S218000, C514S228800, C514S256000, C514S274000, C514S376000, C514S377000, C514S392000, C514S212030, C514S331000, C514S428000

Reexamination Certificate

active

07968707

ABSTRACT:
A compound of the formula:is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

REFERENCES:
patent: 4221789 (1980-09-01), Rodriguez et al.
patent: 4448816 (1984-05-01), Barsa et al.
patent: 4885292 (1989-12-01), Ryono et al.
patent: 5142056 (1992-08-01), Kempe et al.
patent: 5164388 (1992-11-01), De et al.
patent: 5196438 (1993-03-01), Martin et al.
patent: 5354866 (1994-10-01), Kempf et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5484926 (1996-01-01), Dressman et al.
patent: 5541206 (1996-07-01), Kempf et al.
patent: 5635523 (1997-06-01), Kempf et al.
patent: 5643878 (1997-07-01), Bold et al.
patent: 5648497 (1997-07-01), Kempf et al.
patent: 5674882 (1997-10-01), Kempf et al.
patent: 5750648 (1998-05-01), Chang et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5834401 (1998-11-01), Kawamura et al.
patent: 5846987 (1998-12-01), Kempf et al.
patent: 5883252 (1999-03-01), Tung et al.
patent: 5886036 (1999-03-01), Kempf et al.
patent: 5914332 (1999-06-01), Sham et al.
patent: 5945413 (1999-08-01), Tung et al.
patent: 5977027 (1999-11-01), Kawamura et al.
patent: 6017928 (2000-01-01), Kempf et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6284767 (2001-09-01), Sham et al.
patent: 6313296 (2001-11-01), Sham et al.
patent: 6472529 (2002-10-01), Sham et al.
patent: 7279582 (2007-10-01), Stoner et al.
patent: 0 005 689 (1979-11-01), None
patent: 0 342 541 (1989-11-01), None
patent: 0 365 992 (1990-05-01), None
patent: 0 428 849 (1991-05-01), None
patent: 0 486 948 (1992-05-01), None
patent: 0 490 667 (1992-06-01), None
patent: 0 532 466 (1993-03-01), None
patent: 0 560 268 (1993-09-01), None
patent: 0 580 402 (1994-01-01), None
patent: 0 747 352 (1995-08-01), None
patent: 2 773 994 (1998-01-01), None
patent: 89 10752 (1989-11-01), None
patent: 9 208 701 (1992-05-01), None
patent: 93 07128 (1993-04-01), None
patent: 9 323 368 (1993-11-01), None
patent: 94 05639 (1994-03-01), None
patent: 94 14436 (1994-07-01), None
patent: 95 07696 (1995-03-01), None
patent: 95/09614 (1995-04-01), None
patent: 95 20384 (1995-08-01), None
patent: 95 30 670 (1995-11-01), None
patent: 96 05180 (1996-02-01), None
patent: 97 21685 (1997-06-01), None
Y. Becker, et al, “Asymmetric Hydroformylation and Hydrocarboxylation of Enamides. Synthesis of Alanine and Proline”, J. Org. Chem., v45, p. 2145-2151 (1990).
H. Takechi, et al., “Photoreactions of Succinimides with an N-Acyl Group in the Side Chain. Synthesis and Stereochemistry of Tricyclic Pryrrolo[1,2-α] Pyrazine Ring Systems” Chem. Pharm. Bull., v34, No. 8, p. 3142-3152 (1986).
A. Smith, et al., “Pyrrolinone-Based HIV Protease Inhibitors. Design, Synthesis, and Antiviral Activity: Evidence for Improved Transport”, J. Am. Chem. Soc., v117, p. 11113-11123 (1994).
J.Vacca, et al., “Conformationally Constrained HIV-1 Protease Inhibitors”, Bioorganic & Medicianl Chem. Letters, v4, No. 3, p. 499-504 (1994).
R.Randad, “De Novo Design of Nonpeptidic HIV-1 Protease Inhibitors: Incorporation of Structural Water”, Bioorganic & Med. Chem. Let., v4, No. 10, p. 1247-1252 (1994).
D.Scholz, “Inhibitors of HIV-1 Proteinase Containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral Activity”, J. Med. Chem., v37, No. 19, p. 3079-3089 (1994).
J.Jindrich, Synthesis of N—(3-Fluoro-2-Phosphonomethoxypropyl) (FPMP) Derivates of Heterocyclic Bases, Collect. Czech. Chem. Commun., v58, No. 7, p. 1645-1667 (1993).
Kempf, D.J., Design of Orally Bioavailable, Symmetry-Based Inhibitors of HIV Protease, Chem. Abs.., vol. 122, No. 19, 1995 p. 1134.
Kempf, et al, “Peptide Derivatives Preparation as Retroviral Protease Inhibitors”, Chem. Abstracts, v114, No. 25, p. 374 (1991).
Chen, “Expression and Activity-Dependent Changes of a Novel LimBic-Serine Protease Gene in the Hippocampus”, J of Neuroscience, July '195 vol. 15 (7), pp. 5088-50977.
Stone, “Biology Approaches the Teraflop Era”, Science, v256, p. 440-442 (1992).
J. Rudinger, Peptide Hormones (Ed., J A Parson, Jun. 1976: Univ. Park Press), pp. 1-6.
Kumar, G.N. “Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir; a positive drug-drug interaction”, Drug Metab. Dispos., vol. 27(8), pp. 902-908 (1999).
Randad et al., Chemical Abstracts, vol. 133: 105345, 2000.
Tung et al., Chemical Abstracts, Vo. 131, abstract 185247.
Stoner et al., “Synthesis of ABT-378, an HIV Protease Inhibitor Candidate: Avoiding the Use of Carbodimides in a Dufficult Peptide Coupling” Organic Process Research & Development, vol. 3(2): 145-148 (1999).
Stoner et al., “Synthesis of HIV Protease Inhibitor ABT-378 (Lopinavir)” Organic Process Research & Development, vol. 4(4): 264-269 (2000).

Affiliated with

Also associated with

Rating

Retroviral protease inhibiting compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Retroviral protease inhibiting compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral protease inhibiting compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2643021